Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Research & Development (2023 - 2024)

Kura Oncology (KURA) has disclosed Research & Development for 3 consecutive years, with $67.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 62.83% to $67.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $217.9 million, a 45.01% increase, with the full-year FY2025 number at $251.1 million, up 47.72% from a year prior.
  • Research & Development was $67.9 million for Q3 2025 at Kura Oncology, up from $56.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $67.9 million in Q3 2025 to a low of $25.2 million in Q1 2023.
  • A 3-year average of $40.9 million and a median of $38.0 million in 2024 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 40.97% in 2024, then soared 62.83% in 2025.
  • Kura Oncology's Research & Development stood at $32.5 million in 2023, then surged by 60.66% to $52.3 million in 2024, then rose by 29.93% to $67.9 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Research & Development are $67.9 million (Q3 2025), $56.0 million (Q1 2025), and $52.3 million (Q4 2024).